LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2226 | 3694 | 0.6027 | 0.3381 |
| SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2078 | 3694 | 0.5626 | 0.2713 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3080 | 3694 | 0.8338 | 0.7231 |
| SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3742 | 3694 | 1.0130 | 1.0216 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2810 | 3694 | 0.7607 | 0.6013 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1852 | 3694 | 0.5014 | 0.1694 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3474 | 3694 | 0.9406 | 0.9011 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4222 | 3694 | 1.1429 | 1.2381 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 922 | 3694 | 0.2496 | -0.2502 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2843 | 3694 | 0.7696 | 0.6162 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2221 | 3694 | 0.6012 | 0.3357 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4189 | 3694 | 1.1340 | 1.2232 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2870 | 3694 | 0.7771 | 0.6287 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2980 | 3694 | 0.8069 | 0.6783 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3730 | 3694 | 1.0098 | 1.0164 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3729 | 3694 | 1.0095 | 1.0158 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2818 | 3694 | 0.7630 | 0.6052 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4294 | 3694 | 1.1624 | 1.2706 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3031 | 3694 | 0.8206 | 0.7011 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3955 | 3694 | 1.0706 | 1.1177 |
| SK-BR-3 | R406 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3838 | 3694 | 1.0390 | 1.0649 |
| SK-BR-3 | Pictilisib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2191 | 3694 | 0.5931 | 0.3221 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3433 | 3694 | 0.9294 | 0.8824 |
| SK-BR-3 | Geldanamycin | 0.04 | uM | LJP5 | 72 | hr | 1476 | 1472 | 3694 | 0.3985 | -0.0021 |
| SK-BR-3 | Geldanamycin | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1492 | 3694 | 0.4041 | 0.0072 |